123 related articles for article (PubMed ID: 30068702)
1. Overgrowth syndromes and pediatric cancers: how many roads lead to
Bharathavikru R; Hastie ND
Genes Dev; 2018 Aug; 32(15-16):993-995. PubMed ID: 30068702
[TBL] [Abstract][Full Text] [Related]
2. Loss of
Hunter RW; Liu Y; Manjunath H; Acharya A; Jones BT; Zhang H; Chen B; Ramalingam H; Hammer RE; Xie Y; Richardson JA; Rakheja D; Carroll TJ; Mendell JT
Genes Dev; 2018 Jul; 32(13-14):903-908. PubMed ID: 29950491
[TBL] [Abstract][Full Text] [Related]
3. Perlman syndrome: overgrowth, Wilms tumor predisposition and DIS3L2.
Morris MR; Astuti D; Maher ER
Am J Med Genet C Semin Med Genet; 2013 May; 163C(2):106-13. PubMed ID: 23613427
[TBL] [Abstract][Full Text] [Related]
4. Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility.
Astuti D; Morris MR; Cooper WN; Staals RH; Wake NC; Fews GA; Gill H; Gentle D; Shuib S; Ricketts CJ; Cole T; van Essen AJ; van Lingen RA; Neri G; Opitz JM; Rump P; Stolte-Dijkstra I; Müller F; Pruijn GJ; Latif F; Maher ER
Nat Genet; 2012 Feb; 44(3):277-84. PubMed ID: 22306653
[TBL] [Abstract][Full Text] [Related]
5. Long term survival of a patient with Perlman syndrome due to novel compound heterozygous missense mutations in RNB domain of DIS3L2.
Soma N; Higashimoto K; Imamura M; Saitoh A; Soejima H; Nagasaki K
Am J Med Genet A; 2017 Apr; 173(4):1077-1081. PubMed ID: 28328139
[TBL] [Abstract][Full Text] [Related]
6. Mutations in microRNA processing genes in Wilms tumors derepress the
Chen KS; Stroup EK; Budhipramono A; Rakheja D; Nichols-Vinueza D; Xu L; Stuart SH; Shukla AA; Fraire C; Mendell JT; Amatruda JF
Genes Dev; 2018 Aug; 32(15-16):996-1007. PubMed ID: 30026293
[TBL] [Abstract][Full Text] [Related]
7. Role of genomic imprinting in Wilms' tumour and overgrowth disorders.
Reeve AE
Med Pediatr Oncol; 1996 Nov; 27(5):470-5. PubMed ID: 8827076
[TBL] [Abstract][Full Text] [Related]
8. A role for the Perlman syndrome exonuclease Dis3l2 in the Lin28-let-7 pathway.
Chang HM; Triboulet R; Thornton JE; Gregory RI
Nature; 2013 May; 497(7448):244-8. PubMed ID: 23594738
[TBL] [Abstract][Full Text] [Related]
9. Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome.
Sun FL; Dean WL; Kelsey G; Allen ND; Reik W
Nature; 1997 Oct; 389(6653):809-15. PubMed ID: 9349812
[TBL] [Abstract][Full Text] [Related]
10. DIS3L2 Gene Mutation Causes the Perlman Syndrome of Overgrowth and Wilms Tumor Susceptibility.
Al Ghadeer HA; Alghazal FA; Alessa MA; Alghafli JA; Alkhalaf GI; Bumejdad HN; Alherz RM; Alshaikh Saleh RA; Almumtin KA; Abu Sinah AK
Cureus; 2023 Dec; 15(12):e49777. PubMed ID: 38161545
[TBL] [Abstract][Full Text] [Related]
11. Beckwith-Wiedemann syndrome with overlapping Perlman syndrome manifestation.
Ferianec V; Bartova M
J Matern Fetal Neonatal Med; 2014 Oct; 27(15):1607-9. PubMed ID: 24215131
[TBL] [Abstract][Full Text] [Related]
12. The cell type-specific IGF2 expression during early human development correlates to the pattern of overgrowth and neoplasia in the Beckwith-Wiedemann syndrome.
Hedborg F; Holmgren L; Sandstedt B; Ohlsson R
Am J Pathol; 1994 Oct; 145(4):802-17. PubMed ID: 7943172
[TBL] [Abstract][Full Text] [Related]
13. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor 2 and overgrowth: molecular biology and clinical implications.
Morison IM; Reeve AE
Mol Med Today; 1998 Mar; 4(3):110-5. PubMed ID: 9575493
[TBL] [Abstract][Full Text] [Related]
15. The Perlman syndrome DIS3L2 exoribonuclease safeguards endoplasmic reticulum-targeted mRNA translation and calcium ion homeostasis.
Pirouz M; Wang CH; Liu Q; Ebrahimi AG; Shamsi F; Tseng YH; Gregory RI
Nat Commun; 2020 May; 11(1):2619. PubMed ID: 32457326
[TBL] [Abstract][Full Text] [Related]
16. Nephron Progenitor But Not Stromal Progenitor Cells Give Rise to Wilms Tumors in Mouse Models with β-Catenin Activation or Wt1 Ablation and Igf2 Upregulation.
Huang L; Mokkapati S; Hu Q; Ruteshouser EC; Hicks MJ; Huff V
Neoplasia; 2016 Feb; 18(2):71-81. PubMed ID: 26936393
[TBL] [Abstract][Full Text] [Related]
17. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor.
Ravenel JD; Broman KW; Perlman EJ; Niemitz EL; Jayawardena TM; Bell DW; Haber DA; Uejima H; Feinberg AP
J Natl Cancer Inst; 2001 Nov; 93(22):1698-703. PubMed ID: 11717330
[TBL] [Abstract][Full Text] [Related]
18. Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome.
Weksberg R; Shen DR; Fei YL; Song QL; Squire J
Nat Genet; 1993 Oct; 5(2):143-50. PubMed ID: 8252039
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors.
Bjornsson HT; Brown LJ; Fallin MD; Rongione MA; Bibikova M; Wickham E; Fan JB; Feinberg AP
J Natl Cancer Inst; 2007 Aug; 99(16):1270-3. PubMed ID: 17686827
[TBL] [Abstract][Full Text] [Related]
20. Molecular biology of Beckwith-Wiedemann syndrome.
Weksberg R; Squire JA
Med Pediatr Oncol; 1996 Nov; 27(5):462-9. PubMed ID: 8827075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
